Fig. 6

The protein MMP11 level is a prognostic liquid biopsy-based biomarker. A Scheme of the MMP11 ELISA of plasma samples; omPCa: oligometastatic prostate cancer; mPCa: metastatic prostate cancer; pPCa: primary prostate cancer; RT: radiotherapy; CTX: taxane-based chemotherapy; RP: radical prostatectomy. B ELISA analysis of the MMP11 protein levels in the plasma samples (n = 31) from patients with oligometastatic PCa treated with local ablative radiotherapy at the Department of Radiotherapy and Radiation Oncology of the University Hospital Carl Gustav Carus, Dresden (ClinicalTrials.gov Identifier: NCT02264379) and healthy donors (n = 5); *p < 0.05; n.s.- non significant. C The Kaplan–Meier analyses of the association of MMP11 plasma levels and PSA increase (> 2 ng/ml above nadir and 20% above nadir) in patients with oligometastatic PCa treated with local ablative radiotherapy, n = 30. D ELISA analysis of the MMP11 protein levels in plasma samples (n = 43) from patients with primary or metastatic PCa (mPCa) treated with radical prostatectomy (primary PCa) or taxane-based chemotherapy (mPCa), respectively, at the Department of Urology of the University Hospital Carl Gustav Carus, Dresden. ISUP—the International Society of Urological Pathology grade; ***p < 0.001. E The ROC analysis of the discriminatory power of plasma MMP11 levels as a potential blood-based biomarker of metastases. ROC analysis was conducted using ROC Plotter web-tool [56]. The patient characteristics are described in Table 2